| Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. | |
| | |
MedLine Citation:
|
PMID: 21061114 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
BACKGROUND: The OnceMix and INITIATE studies have indicated that biphasic insulin aspart 30 (BIAsp 30) is more effective than insulin glargine (IGlarg), in terms of glycohemoglobin reductions, in patients with type 2 diabetes initiating insulin therapy. The cost-effectiveness of BIAsp 30 versus IGlarg in the Chinese setting is estimated here. METHODS: The validated and peer-reviewed CORE Diabetes Model was used. The nephropathy, retinopathy, and stroke submodels were modified to incorporate available Chinese clinical data. Diabetes complication costs were derived from hospital surveys in Beijing and Chengdu. Simulated cohorts and insulin treatment effects were based on the OnceMix study for once-daily BIAsp 30 versus IGlarg and on the INITIATE study for twice-daily BIAsp 30 versus IGlarg. Life expectancy and direct medical costs were calculated. Projections were made over 30-year time horizons, with costs and life years discounted at 3% annually. Extensive sensitivity analyses were performed, including adjustments to cardiovascular risk for Chinese ethnicity. RESULTS: Once-daily BIAsp 30 increased life expectancy by 0.04 years (12.37 vs. 12.33 years) and reduced direct medical costs by Chinese Yuan (CNY) 59,710 per patient (CNY 229,911 vs. CNY 289,621 per patient) compared with IGlarg in the OnceMix-based analysis. Twice-daily BIAsp 30 increased life expectancy by 0.08 years (12.99 vs. 12.91 years) and reduced direct medical costs by CNY 107,349 per patient (CNY 303,142 vs. CNY 410,491 per patient) compared with IGlarg in the INITIATE-based analysis. Improvements in life expectancy were driven by reduced incidences of most diabetes-related complications. Cost savings were attributable to lower lifetime insulin costs for BIAsp 30 compared with IGlarg in China. Lowered cardiovascular risk for Chinese ethnicity reduced the projected clinical improvements for BIAsp 30 but increased treatment-related lifetime cost savings. CONCLUSIONS: BIAsp 30, either once- or twice-daily, improved projected life expectancy and reduced projected costs compared with IGlarg in the Chinese setting. |
| | |
Authors:
|
James L Palmer; Amélie Beaudet; Jeremy White; Juliette Plun-Favreau; Jayne Smith-Palmer |
Related Documents
:
|
15484714 - A fully symbolic design and modeling of nonlinear glucose control with control system p... 2154344 - Evaluation of determination of lactate dehydrogenase isoenzyme 1 by chemical inhibition... 19508664 - Large impact of antidiabetic drug treatment and hospitalizations on economic burden of ... 15638944 - Systematic reviews of epidemiology in diabetes: finding the evidence. 12728644 - Quantitative trait linkage studies of diabetes-related traits. 231294 - Role of cyclic amp in glucagon-induced stimulation of hepatic glucose output in man. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-10-12 |
Journal Detail:
|
Title: Advances in therapy Volume: 27 ISSN: 1865-8652 ISO Abbreviation: Adv Ther Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-09 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 814-27 Citation Subset: T |
Affiliation:
|
IMS Health, Basel, Switzerland. jpalmer@ch.imshealth.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: [Stoma creation during low anterior resection: the cons].
Next Document: Treatment of acute and chronic peroneal tendon disorders.